Edwards Lifesciences Corp
EW79.330USD
+0.020+0.03%
Handelsschluss 08/01, 16:00（ET）Kurse um 15 Minuten verzögert
46.50BMarktkapitalisierung
11.12KGV TTM
mehr Informationen über Edwards Lifesciences Corp Unternehmen
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Unternehmensinformationen
BörsenkürzelEW
Name des UnternehmensEdwards Lifesciences Corp
IPO-datumMar 27, 2000
Gegründet am1999
CEOMr. Bernard J. Zovighian
Anzahl der mitarbeiter15800
WertpapierartOrdinary Share
GeschäftsjahresendeMar 27
AddresseOne Edwards Way
StadtIRVINE
BörseNYSE Consolidated
LandUnited States of America
Postleitzahl92614
Telefon19492502500
Websitehttps://www.edwards.com
BörsenkürzelEW
IPO-datumMar 27, 2000
Gegründet am1999
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
282.82K
+3.48%
Mr. Larry L. Wood
Mr. Larry L. Wood
Corporate Vice President, Group President - Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart
Corporate Vice President, Group President - Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart
186.44K
--
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
76.00K
+6.56%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
39.57K
+120.44%
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
21.26K
-17.30%
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
19.21K
+44.48%
Mr. Paul A. Laviolette
Mr. Paul A. Laviolette
Independent Director
Independent Director
11.25K
+45.71%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.84K
+152.86%
Mr. Nicholas J. (Nick) Valeriani
Mr. Nicholas J. (Nick) Valeriani
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Kieran T. Gallahue
Mr. Kieran T. Gallahue
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
282.82K
+3.48%
Mr. Larry L. Wood
Mr. Larry L. Wood
Corporate Vice President, Group President - Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart
Corporate Vice President, Group President - Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart
186.44K
--
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
76.00K
+6.56%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
39.57K
+120.44%
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
21.26K
-17.30%
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
19.21K
+44.48%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Transcatheter Aortic Valve Replacement
1.05B
74.09%
Surgical Heart Valve Therapy
250.90M
17.76%
Transcatheter Mitral and Tricuspid Therapies
115.20M
8.15%
Nach RegionUSD
Name
Umsatz
Anteil
United States
838.90M
59.38%
Europe
341.80M
24.19%
Rest of the world
150.20M
10.63%
Japan
81.80M
5.79%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Transcatheter Aortic Valve Replacement
1.05B
74.09%
Surgical Heart Valve Therapy
250.90M
17.76%
Transcatheter Mitral and Tricuspid Therapies
115.20M
8.15%
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
11.75%
BlackRock Institutional Trust Company, N.A.
5.50%
Wellington Management Company, LLP
4.97%
State Street Global Advisors (US)
4.40%
JP Morgan Asset Management
2.79%
Other
70.59%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
11.75%
BlackRock Institutional Trust Company, N.A.
5.50%
Wellington Management Company, LLP
4.97%
State Street Global Advisors (US)
4.40%
JP Morgan Asset Management
2.79%
Other
70.59%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
43.28%
Investment Advisor/Hedge Fund
31.39%
Hedge Fund
5.44%
Research Firm
2.22%
Pension Fund
2.19%
Bank and Trust
1.92%
Sovereign Wealth Fund
1.53%
Individual Investor
0.92%
Endowment Fund
0.82%
Other
10.30%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
2586
529.26M
90.23%
-21.68M
2025Q1
2628
535.29M
91.24%
-19.91M
2024Q4
2597
531.64M
90.42%
-4.10M
2024Q3
2568
511.38M
84.93%
-20.94M
2024Q2
2559
522.19M
86.68%
-12.58M
2024Q1
2572
518.82M
86.18%
-12.08M
2023Q4
2573
509.93M
84.08%
-27.42M
2023Q3
2530
522.96M
86.03%
-18.75M
2023Q2
2517
523.54M
86.35%
-20.02M
2023Q1
2495
522.98M
86.26%
-32.79M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
68.94M
11.75%
+70.46K
+0.10%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
32.28M
5.5%
+544.18K
+1.71%
Mar 31, 2025
Wellington Management Company, LLP
29.13M
4.97%
-4.08M
-12.27%
Mar 31, 2025
State Street Global Advisors (US)
25.78M
4.4%
-25.16K
-0.10%
Mar 31, 2025
JP Morgan Asset Management
16.37M
2.79%
+5.61M
+52.12%
Mar 31, 2025
Citadel Advisors LLC
13.38M
2.28%
+3.96M
+42.09%
Mar 31, 2025
Geode Capital Management, L.L.C.
12.68M
2.16%
-970.48K
-7.11%
Mar 31, 2025
Jennison Associates LLC
10.09M
1.72%
+2.58M
+34.31%
Mar 31, 2025
Fisher Investments
10.10M
1.72%
+325.19K
+3.33%
Mar 31, 2025
Walter Scott & Partners Ltd.
9.06M
1.54%
-347.38K
-3.69%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: 10 hours ago
Aktualisiert: 10 hours ago
Name
Anteil
iShares U.S. Medical Devices ETF
4.56%
Future Fund Long/Short ETF
3.72%
iShares Health Innovation Active ETF
3.18%
Adaptive Core ETF
3.15%
Global X Aging Population ETF
3.13%
Tema Heart & Health ETF
2.28%
First Trust Indxx Medical Devices ETF
2.08%
SPDR S&P Health Care Equipment ETF
1.89%
Invesco S&P 500 Equal Weight Health Care ETF
1.72%
PGIM Jennison Better Future ETF
1.71%
Mehr Anzeigen
iShares U.S. Medical Devices ETF
Anteil4.56%
Future Fund Long/Short ETF
Anteil3.72%
iShares Health Innovation Active ETF
Anteil3.18%
Adaptive Core ETF
Anteil3.15%
Global X Aging Population ETF
Anteil3.13%
Tema Heart & Health ETF
Anteil2.28%
First Trust Indxx Medical Devices ETF
Anteil2.08%
SPDR S&P Health Care Equipment ETF
Anteil1.89%
Invesco S&P 500 Equal Weight Health Care ETF
Anteil1.72%
PGIM Jennison Better Future ETF
Anteil1.71%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
May 07, 2020
Split
1>3
Datum
Art
Verhältnis
May 07, 2020
Split
1>3
